Cargando…
Characterization of “Responder” in patients with Treatment-Resistant Schizophrenia (TRS) treated with a new antipsychotic added to their current antipsychotic monotherapy
INTRODUCTION: Numerous authors have proposed “responder” criteria for patients with schizophrenia treated with antipsychotic monotherapy (Leucht, S et al 2009; 438 7-14; Suzuki T et al, 2012; 197 1-6; Kane J et al 1988; 45 789-96). These suggest reductions greater than 30% on the PANSS total score,...
Autores principales: | Anand, R., Hartman, R., Turolla, A., Chinellato, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661389/ http://dx.doi.org/10.1192/j.eurpsy.2023.1330 |
Ejemplares similares
-
Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study
por: Anand, R., et al.
Publicado: (2023) -
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
por: Anand, Ravi, et al.
Publicado: (2023) -
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005) -
PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016) -
O9.4. RELATIONSHIPS BETWEEN AGE AT ONSET OF PSYCHOTIC SYMPTOMS AND POOR RESPONSE TO ANTIPSYCHOTICS IN A SAMPLE OF TRS/NON-TRS PATIENTS
por: Iasevoli, Felice, et al.
Publicado: (2020)